RCRuihua Cao

Ruihua Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruihua Cao has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Kai Wang

    Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei 230032, China

    3 shared publications
  • Panpan Hu

    Department of Neurology, The First Affiliated Hospital of Anhui Medical University

    3 shared publications
  • Fengbo Xing

    Department of Neurology The First Affiliated Hospital of Anhui Medical University Hefei China

    2 shared publications
  • Jing Wang

    Division of Life Sciences and Medicine, Department of Urologic Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

    2 shared publications
  • Ping Ye

    School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China

    2 shared publications
  • Wenkai Xiao

    Department of Geriatric Cardiology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese People’s Liberation Army General Hospital, Beijing 100039, China

    2 shared publications

Latest Publications

  • Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-synuclein seeding activity

    by Jing Wang, Xixi Sun, Yunfei Yin, Ruihua Cao

    Objective Parkinson’s disease (PD) associated with mutations in the LRRK2 gene exhibits considerable pathological heterogeneity and may not present with Lewy body pathology. The α-Syn seed amplification assay (SAA) performed on cerebrospinal fluid (CSF) has emerged as a reliable in vivo biomarker of α-Syn aggregation. In this study, we aim to investigate the longitudinal trajectories of striatal dopaminergic imaging in LRRK2 PD patients stratified by CSF α-Syn SAA status. Methods Data were obtained from the Parkinson’s Progression Markers Initiative. CSF α-Syn aggregation was assessed using SAA. Striatal DAT-specific binding ratios (SBR) were quantified using [123I] FP-CIT SPECT at baseline, year 2, and year 4. Results At baseline, the α-Syn SAA-negative LRRK2 PD group exhibited higher DAT binding in the contralateral putamen and ipsilateral putamen compared to the SAA-positive group with comparable disease duration. Longitudinally, linear mixed-effects models demonstrated that the α-Syn SAA-negative LRRK2 PD maintained significantly higher DAT binding in both the contralateral and ipsilateral putamen over time. A significant group × time interaction was identified in the contralateral caudate, suggesting a slower rate of DAT loss in the α-Syn SAA-negative group. Sensitivity analyses restricted to participants with complete baseline and follow-up imaging data largely confirmed the main LMEM findings. Conclusions The observed differences in striatal dopaminergic degeneration between LRRK2 PD patients with and without detectable CSF α-synuclein aggregates may reflect region-specific vulnerability to underlying pathological processes. Our findings support the utility of CSF α-Syn SAA status as both a diagnostic and prognostic biomarker in LRRK2 PD.


  • Open Access

    Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-Synuclein Seeding Activity

    by Jing Wang, Xixi Sun, Yunfei Yin, Ruihua Cao

    Objective: Parkinson’s disease (PD) associated with mutations in the LRRK2 gene exhibits considerable pathological heterogeneity and may not present with Lewy body pathology. The α-Syn seed amplification assay (SAA) performed on cerebrospinal fluid (CSF) has emerged as a reliable in vivo biomarker of α-Syn aggregation. In this study, we aim to investigate the longitudinal trajectories of striatal dopaminergic imaging in LRRK2 PD patients stratified by CSF α-Syn SAA status. Methods: Data were obtained from the Parkinson’s Progression Markers Initiative. CSF α-Syn aggregation was assessed using SAA. Striatal DAT specific binding ratios (SBR) were quantified using [¹²³I] FP-CIT SPECT at baseline, year 2, and year 4. Results: At baseline, the α-Syn SAA-negative LRRK2 PD group exhibited higher DAT binding in the contralateral putamen and ipsilateral putamen compared to the SAA-positive group with comparable disease duration. Longitudinally, linear mixed-effects models demonstrated that the α-Syn SAA-negative LRRK2 PD maintained significantly higher DAT binding in both the contralateral and ipsilateral putamen over time. A significant group × time interaction was identified in the contralateral caudate, suggesting a slower rate of DAT loss in the α-Syn SAA-negative group. Sensitivity analyses restricted to participants with complete baseline and follow-up imaging data largely confirmed the main LMEM findings. Conclusions: The observed differences in striatal dopaminergic degeneration between LRRK2 PD patients with and without detectable CSF α-synuclein aggregates may reflect region-specific vulnerability to underlying pathological processes. Our findings support the utility of CSF α-Syn SAA status as both a diagnostic and prognostic biomarker in LRRK2 PD.

  • Open Access

    Reduced Modulation of Theta and Beta Oscillations Mediates Empathy Impairment in Parkinson's Disease

    by Jinying Han, Liuzhenxiong Yu, Mengqi Wang, Xin Chen, Ziye Zhao, Pingping Liu, Lili Hu, Lingling Lv, Fengbo Xing, Ruihua Cao, et al.

    Background: Empathy is an inaccessible part of advanced social cognitive functions in humans. Impairment of empathy greatly affects the quality of life of patients with Parkinson's disease (PD) but the underlying neurophysiologic mechanisms have not been established.Objectives: The dynamic process of brain oscillations in PD pain empathy was explored and the mechanism of empathy damage was studied.Methods: A total of 27 patients with PD and 13 healthy controls were recruited to undergo a pain judgment task, and the event‐related potentials were recorded. This study compared the changes in theta and beta oscillations among two groups after the presentation of painful and neutral stimuli.Results: Time–frequency analysis results revealed that patients with PD exhibited event‐related theta oscillation synchronization and beta oscillation desynchronization during pain empathy. Compared to healthy controls, patients with PD exhibited a reduced magnitude of beta oscillation desynchronization in response to painful stimuli and attenuated synchronization of theta oscillations induced by neutral stimuli. There are abnormal beta power differences between painful and neutral stimuli, while no differences were found in theta power in PD. Moreover, a positive correlation existed between the degree of beta oscillation desynchronization associated with painful stimuli and the accuracy of pain judgments.Conclusion: Pain empathy deficits in PD were associated with reduced dynamic modulation of brain theta and beta oscillations.


  • Open Access

    Association of Remnant-like Particle Cholesterol with Major Adverse Cardiovascular Events in Subjects with Different Levels of Proprotein Convertase Subtilisin/Kexin 9: A 9.5-year Follow-up Study in a Beijing Community Population

    by Xiaona Wang, Ruping Tie, Ruihua Cao, Xu Yang, Wenkai Xiao, Li Sheng, Ping Ye

    Objective: The purpose of this study was to determine the relationship between remnant-like particle cholesterol (RLP-C) and major adverse cardiovascular events (MACEs) in patients with different levels of proprotein convertase subtilisin/kexin 9 (PCSK9). Methods: From September 2007 to January 2009, 1,859 subjects in Pingguoyuan communities in Beijing were initially screened. After excluding those with bedridden status, mental illness, severe systemic diseases, and missing data, 1,680 subjects were recruited for follow up. All recruited subjects were followed up from February 2013 to September 2013 (181 subjects were lost to follow-up) and from June 2017 to September 2018 (174 subjects were lost to follow up). Finally, 1,325 subjects were included in the study. General demographic characteristics, lifestyle and behaviors, disease history and use of medication was collected. Levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fast blood glucose, RLP-C, low-density lipoprotein triglycerides and PCSK9 were measured. The levels of RLP-C (low: RLP-C ≤ 157 mg/L; high: RLP-C > 157 mg/L) and PCSK9 (low: PCSK9 ≤ 135.87 μg/L; high: PCSK9 > 135.87 μg/L) were represented using quartiles. Subjects were categorized into 4 groups according to their RLP-C and PCSK9 levels: Q4, high levels of RLP-C with high levels of PCSK9; Q3, high levels of RLP-C with low levels of PCSK9; Q2, low levels of RLP-C with high levels of PCSK9; and Q1, low levels of RLP-C with low levels of PCSK9. The association of RLP-C with MACEs in subjects with different PCSK9 levels was evaluated. Results: After a median follow-up of 9.5 years, 1,325 subjects were included in the study and a total of 191 MACEs had occurred. The incidence of MACEs was higher in the RLP-C > 157 mg/L group than the RLP-C ≤ 157 mg/L group (18.40% vs. 10.42%). Cox proportional hazards regression model analysis showed that increased RLP-C levels were associated with an increased risk of MACEs (hazard ratio: 1.405; 95% confidence interval: 1.005–1.964; P < 0.005). The incidence of MACEs was higher in the high RLP-C/PCSK9 group vs. the low RLP-C/PCSK9 group (20.68% vs. 8.76%). Cox proportional hazards regression model analysis showed that RLP-C was associated with an increased risk of MACEs in subjects with high PCSK9 levels independent of traditional risk factors (hazard ratio: 1.791; 95% confidence interval: 1.168–2.825; P = 0.001), but not in those with low PCSK9 levels. Conclusions: RLP-C was identified as a risk factor for MACEs, particularly in subjects with high PCSK9 levels. Lowering PCSK9 levels may reduce residual risk in subjects with elevated plasma RLP-C levels.

  • Alterations in event-related potential responses to empathy for pain in Parkinson’s disease on and off medication

    by Panpan Hu, Ruihua Cao, Juan Fang, Qian Yang, Tingting Liu, Fengqiong Yu, Kai Wang


  • Cross‐sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson’s disease

    by Ruihua Cao, Xingui Chen, Fengbo Xing, Chengjuan Xie, Panpan Hu, Kai Wang

    Background and purpose: The aim was to investigate whether probable rapid eye movement sleep behavior disorder (pRBD) is associated with impulse control disorders (ICDs) in drug‐naïve patients with Parkinson’s disease (PD) and whether baseline pRBD is associated with a higher incidence of ICDs during follow‐up.Methods: The Parkinson’s Progression Markers Initiative is an international, multicenter, prospective cohort study to identify biomarkers of PD progression. In all, 423 drug‐naïve patients with early‐stage PD were included in the cross‐sectional analysis, and 320 patients who screened negative for any ICDs or related behaviors at baseline were included in the longitudinal analysis.Results: In the cross‐sectional analysis, a significant correlation was found between pRBD and ICDs in drug‐naïve patients whilst controlling for potential confounders [odds ratio 2.56, 95% confidence interval (CI) 1.38–4.76, P = 0.003]. In the longitudinal analysis, baseline pRBD was an independent predictor of ICD development over time [hazard ratio (HR) 1.648, 95% CI 1.054–2.576; P = 0.028]. Other significant predictors of ICDs included younger age of onset (HR = 0.973, 95% CI = 0.950–0.997; P = 0.026) and greater State‐Trait Anxiety Inventory score (HR = 1.040, 95% CI = 1.020–1.061; P < 0.001).Conclusion: Our data suggest that identifying baseline pRBD in early‐stage PD may help clinicians to choose a better therapeutic strategy so as to prevent or limit neuropsychiatric complications.


  • Open Access

    A higher baseline plasma uric acid level is an independent predictor of arterial stiffness

    by Xiao-Han Ding, Xiaona Wang, Ruihua Cao, Xu Yang, Wenkai Xiao, Yun Zhang, Yongyi Bai, Hongmei Wu, Ping Ye

    Hyperuricemia has been demonstrated to be a risk factor for cardiovascular diseases. Though the association between uric acid (UA) and arterial stiffness has been investigated previously in patients with basic diseases, the predictive value of baseline UA level for arterial stiffness has not been conducted. We aimed at identifying the predictive role of UA for arterial stiffness prospectively. A longitudinal follow-up study in a routine health check-up population was performed with an average follow-up of 4.8 years. The demographic information, baseline and follow-up anthropometric parameters, arterial stiffness (pulse-wave velocity, PWV), and biomarker variables including UA have been measured and analyzed. A total of 1447 valid follow-ups were available for the final analysis. Both of the baseline and follow-up UA levels were significantly higher in the arterial stiffness groups than that in the nonarterial stiffness groups (all P values <0.001). The follow-up carotid-femoral PWV [(cf-PWV), r = 0.161, P < 0.001] was strongly correlated with baseline UA. At the follow-up cross-section, cf-PWV was also closely associated with UA (r = 0.101, P < 0.001). Logistic regressions revealed that a higher baseline UA level was an independent predictor of follow-up arterial stiffness assessed by cf-PWV [odds ratio (OR): 1.824; P = 0.046]. A higher baseline level of UA is closely related to arterial stiffness and is an independent predictor of arterial stiffening.


  • Open Access

    Exploring Biological Motion Processing in Parkinson’s Disease Using Temporal Dilation

    by Ruihua Cao, Xing Ye, Xingui Chen, Long Zhang, Xianwen Chen, Yanghua Tian, Panpan Hu, Kai Wang

    Biological motion (BM) perception is the compelling ability of the visual system to perceive complex animated movements effortlessly and promptly. A recent study has shown that BM can automatically lengthen perceived temporal duration independent of global configuration. The present study aimed mainly to investigate this temporal dilation effect of BM signals in Parkinson’s disease (PD) patients. We used the temporal dilation effect as an implicit measure of visual processing of BM. In all, 32 PD patients (under off-therapy conditions) and 32 healthy controls (HCs) participated in our study. In each trial, an upright BM sequence and an inverted BM sequence were presented within an interval in the center of the screen. We tested both canonical and scrambled BM sequences; the scrambled ones were generated by disturbing the global configuration of the canonical ones but preserving exactly the same local motion components. Observers were required to make a verbal two-alternative forced choice response to indicate which interval (the first or the second) appeared longer. Statistical analyses were conducted on the points of subjective equality (PSEs). We found that the temporal dilation effect was significantly reduced for PD patients compared with HCs in both canonical and scrambled BM conditions. Moreover, no temporal dilation effects of scrambled BM were shown in both early- and late-stage PD patients, while the temporal dilation effect of canonical BM was relatively preserved in the early stages.